Perrigo, already facing pressure from activist investors, is also dealing with another recall, this time for a prescription acne med that has some mold issues.
According to the most recent FDA Enforcement Report, the Dublin-based company several weeks ago began voluntarily recalling 10 lots of clindamycin phosphate and benzoyl peroxide gel. That amounts to 162,534 tubes of the generic version of Duac Gel.
The report says that a small number of tubes of the nonsterile gel may include the presence of mold on the cap. The med is manufactured at a Perrigo plant in Israel.
Perrigo had several significant recalls last year, including 200 million doses of a medication used to fight infections like diaper rash and thrush after a labeling mishap. It also recalled its copy of children's grape-flavored Mucinex after learning that dosing cups may be mismarked, putting children at risk for being overdosed.
Perrigo has been under pressure from Starboard Value, a hedge fund that owns about 4.6% of the company and which has slammed Perrigo's “woeful” performance. In December, Perrigo said one step it would take to improve its margins was to restructure its Omega Pharma Belgium business. As part of that move, it expects to cut about 80 jobs.